Skip to content

Clinical effect of drinking hydrogen-rich water on patients with hyperuricemia

Clinical effect of drinking hydrogen-rich water on patients with hyperuricemia

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200066369
Enrollment
Unknown
Registered
2022-12-02
Start date
2022-12-26
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hyperuricemia

Interventions

Control group:Drinking ordinary drinking water and health management
Intervention group:Drinking hydrogen-rich water and health management

Sponsors

The Second Affiliated Hospital of Shandong First Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: ? It meets the diagnostic criteria. According to the Chinese Guidelines for Diagnosis and Treatment of Hyperuricemia and Gout (2019), the diagnostic criteria for hyperuricemia are: In both males and females, the serum uric acid level exceeded 420 µmol/L twice on different days. Self-reported doctor diagnosed hyperuricemia; ? BMI of 18.5 to 26.0 kg/m2; ? Age 18-70 years old; ? Clear consciousness, able to understand and answer questions. Patients voluntarily participated in the experiment and signed informed consent.

Exclusion criteria

Exclusion criteria: ? gouty arthritis acute stage; ? Patients with kidney stones; ? Secondary elevated serum uric acid caused by tumor and other factors; ? Those who have recently taken uric acid lowering drugs or drugs that affect uric acid level; ? Patients with autoimmune and hematopoietic diseases or severe liver and kidney insufficiency or gastrointestinal problems; ? Mental and psychological disorders or serious heart and brain lesions; ?Patients with severe primary diseases such as cardiovascular and cerebrovascular diseases, liver and biliary diseases, lung diseases, acute infections and malignant hypertension; ?Pregnancy and breastfeeding women; ? Poor compliance or inability to cooperate with the examination affecting clinical investigators.

Design outcomes

Primary

MeasureTime frame
Blood uric acid level;

Secondary

MeasureTime frame
blood lipids (TC?TG?LDLc?HDLc);blood glucose;TNF-? level;MDA level;

Countries

China

Contacts

Public ContactShucun Qin

The Second Affiliated Hospital of Shandong First Medical University

scqin@sdfmu.edu.cn+86 13583815481

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 6, 2026